NSCLC non-metastatic

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 06/05/2022)

MERMAID-1 (AstraZeneca)
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer.

PACIFIC-4 (AstraZeneca)
International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515). (Closed for T1a and T1b)